HC Wainwright Reaffirms Buy Rating for Pharming Group (NASDAQ:PHAR)

HC Wainwright reaffirmed their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a $37.00 price target on the stock.

Several other research analysts have also commented on the stock. Oppenheimer dropped their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Jefferies Financial Group started coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price for the company.

Pharming Group Price Performance

NASDAQ:PHAR opened at $8.98 on Wednesday. The firm has a market capitalization of $609.27 million, a price-to-earnings ratio of -34.55 and a beta of 0.05. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business has a 50 day simple moving average of $8.27 and a 200-day simple moving average of $8.15. Pharming Group has a 1 year low of $6.65 and a 1 year high of $13.20.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group (NASDAQ:PHAR) by 75.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.